Floatz logo

15 assets in Vulva Cancer

Therapeutic assets addressing Vulva Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Indocyanine Green
Vulva Cancer
Istanbul UniversityP4BB (70)
e7 tcr-t cells
Vulva Cancer
Christian HinrichsP2B (60)
Pembrolizumab
Vulva Cancer
UNICANCERP2B (57)
Adriamycin
Vulva Cancer
Yonsei UniversityP2CCC (53)
Belzutifan
Vulva Cancer
Dana-Farber Cancer InstituteP2CCC (53)
Dostarlimab
Vulva Cancer
Yonsei UniversityP2CCC (53)
Atezolizumab
Vulva Cancer
University of FloridaP1/2CC (47)
Carbon Nanoparticle-Loaded Iron
Vulva Cancer
Sichuan Enray Pharmaceutical Sciences CompanyP1/2CC (47)
Entinostat
Vulva Cancer
National Cancer Institute (NCI)P1/2CC (47)
pds01adc
Vulva Cancer
National Cancer Institute (NCI)P1/2CC (47)
Tivozanib
Vulva Cancer
University of FloridaP1/2CC (47)
Cnsi-Fe
Vulva Cancer
Sichuan Enray Pharmaceutical Sciences CompanyP1CC (46)
Immunotherapic Bifunctional Fusion Protein Comprised Of A Fully Human Igg1 Monoclonal Antibody (Avelumab) Against Human Programmed Death-Ligand 1 (Pd-L1) Fused To The Soluble Extracellular Domain Of Transforming Growth Factor-.Beta. (Tgf-.Beta.) Receptor Ii, Which Acts As A Tgf-.Beta. Trap
Vulva Cancer
National Cancer Institute (NCI)P1/2CC (44)
scg142 tcr-t cells
Vulva Cancer
The Affiliated Hospital of Qingdao UniversityP1CC (43)